The changing pattern of epidemiology in hepatocellular carcinoma
- PMID: 20547305
- PMCID: PMC3392755
- DOI: 10.1016/S1590-8658(10)60507-5
The changing pattern of epidemiology in hepatocellular carcinoma
Abstract
Primary liver cancer (PLC) represents approximately 4% of all new cancer cases diagnosed worldwide. The purpose of this review is to describe some of the latest international patterns in PLC incidence and mortality, as well as to give an overview of the main etiological factors. We used two databases, GLOBOCAN 2002 and the World Health Organization (WHO) mortality database to analyze the incidence and mortality rates for PLC in several regions around the world. The highest age adjusted incidence rates (>20 per 100,000) were reported from countries in Southeast Asia and sub-Saharan Africa that are endemic for HBV infection. Countries in Southern Europe have medium-high incidence rates, while low-incidence areas (<5 per 100,000) include South and Central America, and the rest of Europe. Cirrhosis is present in about 80-90% of HCC patients and is thereby the largest single risk factor. Main risk factors include HBV, HCV, aflatoxin and possibly obesity and diabetes. Together HBV and HCV account for 80-90% of all HCC worldwide. HBV continues to be the major HCC risk factor worldwide, although its importance will most likely decrease during the coming decades due to the widespread use of the HBV vaccine in the newborns. HCV has been the dominant viral cause in HCC in North America, some Western countries and Japan. Obesity and diabetes are increasing at a fast pace throughout the world, and if they are proven to be HCC risk factors, they would account for more HCC cases in the future.
Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The corresponding author has received a fee from Bayer HealthCare for his contribution to this supplement. Bayer HealthCare played no role in the preparation, review, or approval of the manuscript. The co-authors have no conflict of interest to report.
Figures




Similar articles
-
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014. Gastroenterology. 2004. PMID: 15508101 Review.
-
Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan.J Gastroenterol Hepatol. 2007 Jan;22(1):92-8. doi: 10.1111/j.1440-1746.2006.04489.x. J Gastroenterol Hepatol. 2007. PMID: 17201888
-
Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.J Viral Hepat. 2022 May;29(5):352-365. doi: 10.1111/jvh.13663. Epub 2022 Mar 15. J Viral Hepat. 2022. PMID: 35274406
-
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.Oncologist. 2010;15 Suppl 4:5-13. doi: 10.1634/theoncologist.2010-S4-05. Oncologist. 2010. PMID: 21115576 Review.
-
Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma.Pathol Biol (Paris). 2010 Aug;58(4):273-7. doi: 10.1016/j.patbio.2010.01.005. Epub 2010 Apr 7. Pathol Biol (Paris). 2010. PMID: 20378277
Cited by
-
Recent progress in treatment of hepatocellular carcinoma.Am J Cancer Res. 2020 Sep 1;10(9):2993-3036. eCollection 2020. Am J Cancer Res. 2020. PMID: 33042631 Free PMC article. Review.
-
Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis.Int J Clin Exp Med. 2015 May 15;8(5):6638-49. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26221201 Free PMC article. Review.
-
A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors.Dis Model Mech. 2013 Mar;6(2):414-23. doi: 10.1242/dmm.010462. Epub 2012 Oct 4. Dis Model Mech. 2013. PMID: 23038063 Free PMC article.
-
Hepatocellular Carcinoma in Diabetic Patients - a Single Center Experience.Curr Health Sci J. 2016 Apr-Jun;42(2):180-187. doi: 10.12865/CHSJ.42.02.10. Epub 2016 Jun 28. Curr Health Sci J. 2016. PMID: 30568830 Free PMC article.
-
Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis.World J Gastroenterol. 2019 Feb 7;25(5):567-583. doi: 10.3748/wjg.v25.i5.567. World J Gastroenterol. 2019. PMID: 30774272 Free PMC article.
References
-
- Stewart BW, Kleihues P, editors. World Cancer Report. Lyon: IARC Press; 2003.
-
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. - PubMed
-
- Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211. - PubMed
-
- Bosetti C, Bianchi C, Negri E, et al. Estimates of the incidence and prevalence of hepatocellular carcinoma in Italy in 2002 and projections for the years 2007 and 2012. Tumori. 2009;95(1):23–7. - PubMed
-
- Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer. 2007;121(7):1624–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical